| Literature DB >> 23227318 |
Rodrigo Cartin-Ceba1, Markos Kashiouris, Maria Plataki, Daryl J Kor, Ognjen Gajic, Edward T Casey.
Abstract
Background. Acute kidney injury (AKI) is a frequent complication of critically ill patients. The impact of different risk factors associated with this entity in the ICU setting is unknown. Objectives. The purpose of this research was to assess the risk factors associated with the development of AKI in critically ill patients by meta-analyses of observational studies. Data Extraction. Two reviewers independently and in duplicate used a standardized form to collect data from published reports. Authors were contacted for missing data. The Newcastle-Ottawa scale assessed study quality. Data Synthesis. Data from 31 diverse studies that enrolled 504,535 critically ill individuals from a wide variety of ICUs were included. Separate random-effects meta-analyses demonstrated a significantly increased risk of AKI with older age, diabetes, hypertension, higher baseline creatinine, heart failure, sepsis/systemic inflammatory response syndrome, use of nephrotoxic drugs, higher severity of disease scores, use of vasopressors/inotropes, high risk surgery, emergency surgery, use of intra-aortic balloon pump, and longer time in cardiopulmonary bypass pump. Conclusion. The best available evidence suggests an association of AKI with 13 different risk factors in subjects admitted to the ICU. Predictive models for identification of high risk individuals for developing AKI in all types of ICU are required.Entities:
Year: 2012 PMID: 23227318 PMCID: PMC3513719 DOI: 10.1155/2012/691013
Source DB: PubMed Journal: Crit Care Res Pract ISSN: 2090-1305
Figure 1Flow diagram of the process of study selection.
Description of studies included in the systematic review and meta-analysis.
| First author, year | Setting/country | Study design/number of centers | Years of enrollment | Total sample, % men | AKI definition | Incidence of AKI in the study | Severity of disease score, mean standard deviation (SD) |
|---|---|---|---|---|---|---|---|
| Hilberman 1979 [ | Surgical-Cardiac/USA | PC/1 | 1977-1978 | 226/NR | Need for RRT of peritoneal dialysis or BUN > 70 mg/dL or GFR < 30 mL/min/m2 | 14.6% | NR |
| Wilkins and Faragher 1983 [ | Mixed/UK | HC/1 | 1976–1979 | 475/51 | Creatinine > 180 | 23% | NR |
| Corwin 1989 [ | Surgical-Cardiac/USA | CC/1 | 1985 | 84/NR | ↓ Creatinine 50% of baseline | N/A | NR |
| Boucher 1990 [ | Surgical-Trauma/USA | CC/1 | 1988-1989 | 184/76 | ↑ Creatinine ≥ 0.5 mg/dL from baseline or ↑ creatinine > 50% baseline | N/A | ISS (28 ± 13) |
| Groeneveld 1991 [ | Medical/Netherlands | HC/1 | 1986-1987 | 487/52 | ↑ Creatinine ≥ 3.2 mg/dL or ↑ creatinine more than 2 times the baseline | 16% | NR |
| Tran 1994 [ | Surgical-Trauma/Netherlands | HC/1 | 1985–1989 | 206/73 | ↑ Creatinine ≥ 3.2 mg/dL or ↑ creatinine more than 2 times the baseline | 15% | ISS (39 ± 17.6) |
| Zanardo 1994 [ | Surgical-Cardiac/Italy | PC/1 | 1989–1999 | 734/68 | ↑ Creatinine ≥ 2.5 mg/dL | 3.7% | NR |
| Ward 1996 [ | Medical/USA | HC/1 | NR | 102/53 | ↑ Creatinine ≥ 0.5 mg/dL from baseline | 17.6% | APACHE II |
| Vivino 1998 [ | Surgical-Trauma/Italy | PC/1 | 1991–1994 | 153/80 | ↑ Creatinine ≥ 2 mg/dL or ↑ creatinine > 20% of baseline | 31% | ISS (28.1 ± 11) |
| Mangano 1998 [ | Surgical-Cardiac/USA | PC/24 | 1991–1993 | 2,222/76 | ↑ Creatinine > 177 | 7.7% | NR |
| Conlon 1999 [ | Surgical-Cardiac/USA | PC/1 | 1995–1997 | 2,672/64 | ↑ Creatinine ≥ 1 mg/dL from baseline | 8% | NR |
| De Mendonça 2000 [ | Mixed/16 countries | PC/40 | May 1995 | 1411/NR | ↑ Creatinine ≥ 3.5 mg/dL and/or urine output < 500 mL/24 hours | 24.7% | NR |
| Ficher 2002 [ | Surgical-Cardiac/Germany | CC/1 | 1999-2000 | 143/73 | ↑ Creatinine ≥ 0.5 mg/dL from baseline or RRT | N/A | NR |
| Clermont 2002 [ | Mixed/USA | PC/1 | NR | 1530/NR | ↑ Creatinine ≥ 0.5 mg/dL if baseline ≤ 1.9 mg/dL, or ↑ creatinine ≥ 1 mg/dL if baseline ≥ 2 to ≤ 4.9 mg/dL, or ↑ creatinine ≥ 1.5 mg/dL if baseline ≥ 5 mg/dL | 17.2% | APACHE III |
| Bove 2004 [ | Surgical-Cardiac/Italy | PC/1 | 1998–2002 | 5,068/67 | ↑ Creatinine ≥ 100% from baseline | 3.4% | NR |
| Bahar 2005 [ | Surgical-Cardiac/Turkey | HC/1 | 1991–2001 | 14,437 | ↑ Creatinine ≥ 100% from baseline 24 hours after surgery or sustained urine output < 20 mL/hour | 1.2% | NR |
| Chawla 2005 [ | Mixed/USA | PC/1 | 2002-2003 | 194/53 | ↑ Creatinine > 75% from baseline if creatinine ≤ 2 mg/dL or ↑ creatinine > 50% from baseline if creatinine > 2 mg/dL | 18% | APACHE II |
| Loef 2005 [ | Surgical-Cardiac/Netherlands | HC/1 | 1991 | 843/73 | ↑ Creatinine ≥ 25% of baseline creatinine during first week after surgery | 17.2% | NR |
| Mataloun 2006 [ | Mixed, Brazil | PC/1 | 1999-2000 | 221/46 | ↑ Creatinine ≥ 1.5 mg/dL | 19% | APACHE II |
| Hoste 2006 [ | Mixed/USA | HC/1 | 2000-2001 | 5,383/51 | RIFLE | 67% | APACHE III |
| Landoni 2007 [ | Surgical-Cardiac/Italy | PC/1 | 1998–2003 | 3,103/84 | ↑ Creatinine > 100% from baseline | 2.2% | NR |
| Barrantes 2008 [ | Medical/USA | HC/1 | 2005 | 381/57 | ↑ Creatinine ≥ 0.3 mg/dL or ≥ 50% from baseline and/or an episode of < 0.5 mL/Kg/hr urine output for > 6 hours despite fluid challenge of ≥ 500 mL of normal saline | 31.5% | APACHE II |
| Bagshaw 2008 [ | Mixed/Australia and New Zealand | HC/57 | 2000–2005 | 120,123/59 | RIFLE (only cases in first 24 hours of admission), modified urine output criteria | 36% | APACHE II |
| Bagshaw 2008 [ | Surgical-Trauma/Australia and New Zealand | HC/57 | 2000–2005 | 9,449/70 | RIFLE (only cases in first 24 hours of admission), modified urine output criteria | 18.1% | APACHE II |
| Dasta 2008 [ | Surgical-Cardiothoracic/USA | NCC/1 | 1998–2002 | 3,741/63 | RIFLE creatinine criterion | 6.9% | APACHE III |
| Abelha 2009 [ | Surgical-NonCardiac/Portugal | HC/1 | 2006–2008 | 1,166/65 | ↑ Creatinine ≥ 0.3 mg/dL or ≥ 50% from baseline and/or an episode of < 0.5 mL/Kg/hr urine output for >6 hours despite a ≥500 ml fluid challenge | 7.5% | APACHE II median (IQR) |
| De Ara | Surgical-Cardiac/Brazil | HC/1 | 2003–2006 | 186/59 | ↑ Creatinine > 50% from baseline if creatinine > 1.3 mg/dL or ↑ creatinine > 0.5 mg/dL from baseline if creatinine < 1.3 mg/dL, or need of RRT | 30.6% | NR |
| Thakar 2009 [ | Mixed/USA | HC/191 | 2001–2006 | 325,395/97 | ↑ Creatinine ≥ 0.3 mg/dL from baseline | 22% | NR |
| Hobson 2009 [ | Surgical-Cardiothoracic/USA | HC/1 | 1992–2002 | 2973/66 | RIFLE creatinine criterion | 43% | NR |
| Machado 2009 [ | Surgical-Cardiac/Brazil | HC/1 | 2003–2008 | 817/70 | ↑ Creatinine ≥ 0.3 mg/dL or ≥50% from baseline | 48.5% | EuroSCORE, median (IQR) |
| Gomes 2010 [ | Surgical-Trauma/Portugal | HC/1 | 2001–2007 | 436/80 | RIFLE | 50% | ISS |
AKI: acute kidney injury, SD: standard deviation, BUN: blood urea nitrogen, GFR: glomerular filtration rate, HC: historical cohort, PC: prospective cohort, CC: case-control, NCC: nested case control, RRT: renal replacement therapy, NR: not reported, IQR: interquartile range, ISS: injury severity score, APACHE: acute physiologic and chronic health evaluation score, RIFLE: risk injury failure loss end stage kidney disease criteria, EuroSCORE: European System for Cardiac Operative Risk Evaluation.
To convert μmol/dL to mg/dL, divide by 88.
Quality of the studies utilizing the Newcastle-Ottawa quality assessment scale (maximum score of 9).
| Cohort studies | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Selection | Comparability | Outcome | Total score | ||||||
| First author, year | Representativeness of exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Demonstration that outcome was not present at start of study | Comparability | Assessment of outcome | Followup long enough | Adequacy of followup of cohorts | |
| Hilberman | ∗ | ∗ | ∗ | ∗ | 4 | ||||
| Wilkins 1983 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| Groeneveld 1991 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 7 | |
| Tran 1994 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| Zanardo 1994 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 8 |
| Ward 1996 [ | ∗ | ∗ | ∗ | 3 | |||||
| Vivino 1998 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 8 |
| Mangano 1998 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 8 |
| Conlon 1999 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| De Mendonça 2000 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 7 | |
| Clermont 2002 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| Bove 2004 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 8 |
| Bahar 2005 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| Chawla 2005 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| Loef 2005 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| Mataloun 2006 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 7 | |
| Hoste 2006 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 7 | |
| Landoni 2007 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 7 | |
| Barrantes 2008 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
| Bagshaw 2008 [ | ∗ | ∗ | ∗ | ∗ | ∗ | 5 | |||
| Bagshaw et al., 2008 [ | ∗ | ∗ | ∗ | ∗ | ∗ | 5 | |||
| Abelha 2009 [ | ∗ | ∗ | ∗ | ∗ | 4 | ||||
| De Araújo Brito 2009 [ | ∗ | ∗ | ∗ | ∗ | 4 | ||||
| Thakar 2009 [ | ∗ | ∗ | ∗ | ∗ | 4 | ||||
| Hobson 2009 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 7 | |
| Machado 2009 [ | ∗ | ∗ | ∗ | ∗ | 4 | ||||
| Gomes 2010 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
|
| |||||||||
| Case-control studies | |||||||||
| Selection | Comparability | Exposure | Total score | ||||||
| First author, year | Case definition adequate | Representiveness | Selection of controls | Definition of controls | Comparability | Ascertainment of exposure | Same ascertainment method | Nonresponse rate | |
|
| |||||||||
| Corwin 1989 [ | ∗ | ∗ | ∗ | 3 | |||||
| Boucher 1990 [ | ∗ | ∗ | ∗ | ∗∗ | ∗ | ∗ | ∗ | 8 | |
| Ficher 2002 [ | ∗ | ∗ | ∗ | ∗ | 4 | ||||
| Dasta 2008 [ | ∗ | ∗ | ∗ | ∗ | ∗ | ∗ | 6 | ||
Risk factors for acute kidney Injury evaluated in 31 observational studies.
| Age (years) | Diabetes | Hypertension | Baseline creatinine (mg/dL) | Heart failure | Sepsis/ | Nephrotoxic drugs | Severity of disease | Hypotension/ | Pressors/ | High risk surgery/ | Cardiopulmonary bypass time (minutes) | IABP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hilberman |
|
| |||||||||||
| Wilkins 1983 [ | ⚪ | ⚪ | ⚪ |
|
|
|
| N/A | N/A | ||||
| Corwin |
| ⚪ | ⚪ |
|
| ⚪ | ⚪ | ||||||
| Boucher 1990 [ | ⚪ | ⚪ | ⚪ |
| ⚪ |
| N/A | N/A | |||||
| Groeneveld 1991 [ | ⊙ |
| N/A | N/A | N/A | ||||||||
| Tran | ⚪ |
|
| N/A | N/A | ||||||||
| Zanardo | ⊙ |
| ⊙ |
| ⊙ | ||||||||
| Ward |
| ⊙ | ⊙ | N/A | N/A | N/A | |||||||
| Vivino | ⊙ | ⚪ | ⚪ | ⊙ |
| N/A | N/A | ||||||
| Mangano 1998 [ | ⊙ | ⊙! |
| ⊙ | ⊙ | ⊙ |
| ⊙ |
| ||||
| Conlon 1999 [ | ⊙ | ⊙ | ⊙ |
| ⊙ |
| |||||||
| De Mendonça 2000 [ | ⊙ | ⊙ | ⊙ | ⚪ | N/A | N/A | |||||||
| Ficher et al., 2002 [ | ⚪ | ⚪ | ⚪ |
|
| ||||||||
| Clermont | ⚪ |
|
| N/A | N/A | ||||||||
| Bove | ⊙ |
| ⊙ | ⊙ | ⊙ | ⊙ | ⊙ | ||||||
| Bahar | ⊙ |
|
|
|
|
| ⊙ | ⊙ | |||||
| Chawla 2005 [ | ⚪ | ⚪ | ⚪ | ⚪ | ⊙ | ⚪ |
| ⚪ | ⚪ | N/A | N/A | ||
| Loef |
| ⚪ | ⚪ | ⚪ | ⚪ | ⚪ |
|
|
| ||||
| Mataloun | ⚪ | ⚪ | ⚪ | ⚪ |
| ⚪ | ⚪ | ⊙ |
| ⚪ | N/A | N/A | |
| Hoste | ⊙ | ⊙ | ⊙ | N/A | N/A | ||||||||
| Landoni | ⊙ | ⚪ | ⊙ | ⊙ | ⊙ |
|
| ||||||
| Barrantes |
|
|
|
|
| N/A | N/A | N/A | |||||
| Bagshaw et al., |
|
|
|
|
| N/A | N/A | ||||||
| Bagshaw |
|
|
| N/A | N/A | ||||||||
| Dasta | ⚪* | ⚪ |
|
| ⚪* | ||||||||
| Abelha 2009 [ |
| ⚪ | ⊙ |
| ⊙ | N/A | N/A | ||||||
| De Araújo Brito 2009 [ | ⚪ | ⚪ | ⚪ | ⚪ |
|
|
| ||||||
| Thakar 2009 [ |
|
|
|
|
| N/A | N/A | ||||||
| Hobson |
| ⚪ | ⚪ |
|
|
|
| ||||||
| Machado |
|
|
|
| ⚪ | ⚪ | |||||||
| Gomes | ⚪ |
| N/A | N/A | |||||||||
| Number of studies pooled for Meta-analysis | 26 | 15 | 9 | 10 | 14 | 8 | 7 | 10 | 8 | 7 | 10 | 9 | 11 |
| Number of patients | 172,710 | 359,163 | 347,484 | 31,740 | 346,503 | 122,240 | 2,341 | 133,668 | 5,046 | 18,418 | 147,384 | 27,984 | 33,198 |
| OR (95% CI) | 1.52 [1.27, 1.82] | 1.15 [0.76, 1.74] | 1.97 [1.65, 2.35] | 3.56 [1.85, 6.85] | 1.54 [1.14, 2.08] | 2.89 [1.54, 5.42] | 4.75 [2.51, 8.99] | 2.34 [1.59, 3.43] | 3.29 [2.21, 4.91] | ||||
| Mean difference (95% CI) | 5.36 [3.72, 6.99] | 0.22 [0.02, 0.41] | 7.09 [4.86, 9.32] | 27.92 [14.41, 41.43] | |||||||||
|
| 97% | 80% | 96% | 99% | 74% | 95% | 42% | 100% | 84% | 88% | 94% | 94% | 80% |
Cases and controls were matched on age and APACHE III. !Only type 1 diabetes assessed.
SIRS: systemic inflammatory response syndrome, IABP: intra-aortic balloon pump, CI: confidence interval, OR: odds ratio.
⚪ Risk assessed, no significant difference between groups.
● Risk assessed, significant difference between groups in unadjusted comparison.
⊙ Risk assessed, significant difference between groups in adjusted comparison.
N/A: not applicable (risk assessed only for cardiac surgery studies).
Subgroups analysis.
| Risk Factor | Number of studies | Odds ratio or mean difference* (95% CI) |
| Inconsistency |
|---|---|---|---|---|
| Age | ||||
| Surgical | 17 | 5.35 [2.84, 7.86] | 0.99 | 96% |
| Mixed | 6 | 4.95 [2.27–7.63] | 0.81 | 97% |
| Medical | 3 | 7.61 [4.77, 10.44] | 0.17 | 0% |
| Diabetes | ||||
| Surgical | 11 | 1.61 [1.41, 1.83] | 0.61 | 31% |
| Mixed | 4 | 1.09 [1.07, 1.11] | <0.001 | 0% |
| Hypertension | ||||
| Surgical | 7 | 1.34 [1.04, 1.73] | 0.53 | 68% |
| Mixed | 2 | 0.68 [0.45, 1.05] | 0.08 | 49% |
| Baseline creatinine* | ||||
| Surgical | 8 | 0.20 [−0.02, 0.42] | 0.89 | 99% |
| Heart Failure | ||||
| Surgical | 9 | 2.19 [1.92, 2.5] | 0.34 | 8% |
| Mixed | 4 | 1.51 [1.47, 1.55] | 0.003 | 0% |
| Sepsis/SIRS | ||||
| Surgical | 2 | 2.69 [1.28, 5.64] | 0.57 | 47% |
| Mixed | 4 | 2.52 [1.36, 4.69] | 0.45 | 87% |
| Medical | 2 | 8.58 [1.56, 47.22] | 0.34 | 95% |
| Nephrotoxic drugs | ||||
| Surgical | 4 | 1.25 [0.92, 1.71] | 0.34 | 0% |
| Mixed | 2 | 2.12 [1.04, 4.32] | 0.41 | 64% |
| Severity of disease* | ||||
| Surgical | 5 | 5.69 [3.25, 8.14] | 0.40 | 88% |
| Mixed | 3 | 10.66 [3.37, 17.95] | 0.35 | 96% |
| Medical | 2 | 5.32 [3.98, 6.65] | 0.18 | 0% |
| Hypotension/shock | ||||
| Surgical | 4 | 2.48 [1.3, 4.72] | 0.74 | 57% |
| Mixed | 4 | 3.44 [1.09, 10.89] | 0.79 | 92% |
| Pressors/inotropes | ||||
| Surgical | 5 | 5.36 [2.39, 12.03] | 0.81 | 91% |
| Mixed | 2 | 3.41 [1.87, 6.20] | 0.45 | 19% |
| High risk surgery/emergency surgery | ||||
| Surgical | 6 | 3.79 [2.91, 4.94] | 0.04 | 33% |
| Mixed | 4 | 1.14 [0.64, 2.02] | 0.04 | 91% |
CI: confidence interval, SIRS: systemic inflammatory response syndrome.
Sensitivity analysis.
| Risk factor | Number of studies excluded | Odds ratio or mean difference* (95% CI) |
| Inconsistency |
|---|---|---|---|---|
| Age | 9 | 4.95 [3.79, 6.12] | 0.69 | 80% |
| Diabetes | 4 | 1.58 [1.36, 1.84] | 0.74 | 36% |
| Hypertension | 4 | 1.43 [1.08, 1.89] | 0.39 | 73% |
| Baseline creatinine* | 3 | 0.14 [0.01, 0.27] | 0.50 | 94% |
| Heart failure | 2 | 2.05 [1.77, 2.38] | 0.73 | 27% |
| Sepsis/SIRS | 1 | 4.15 [2.36, 7.32] | 0.72 | 83% |
| Nephrotoxic drugs | 1 | 1.53 [1.09, 2.14] | 0.97 | 52% |
| Severity of disease* | 4 | 9.08 [4.57, 13.60] | 0.43 | 94% |
| Hypotension/shock | 1 | 3.33 [1.70, 6.52] | 0.76 | 84% |
| Pressors/inotropes | 2 | 4.52 [2.03, 10.05] | 0.92 | 92% |
| High risk surgery/emergency surgery | 2 | 2.34 [1.23, 4.49] | 0.99 | 92% |
| Cardiopulmonary bypass time* | 3 | 30.46 [23.41, 37.51] | 0.74 | 59% |
| IABP | 3 | 3.76 [2.54, 5.57] | 0.64 | 78% |
CI: confidence interval, SIRS: Systemic inflammatory response syndrome, IABP: intra-aortic balloon pump.